KCG
ORKA

Knight Capital Group’s Oruka Therapeutics ORKA Stock Holding History

Knight Capital Group’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q2 		$150K Buy
+77
New +$235K ﹤0.01% 2824

Other funds holding ORKA

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Knight Capital Group's ORKA Position: Q2 2013 in Review

Knight Capital Group opened a new position in Oruka Therapeutics (ORKA) in Q2 2013: 77 shares worth $150K. The stake represents ﹤0.01% of the portfolio and ranks #2824 among its holdings.

12 funds tracked by Wall St. Rank hold ORKA as of Q2 2013.

  • Knight Capital Group held 77 shares of Oruka Therapeutics worth $150K as of Q2 2013.
  • Oruka Therapeutics was a new Knight Capital Group position in Q2 2013.
  • Oruka Therapeutics made up ﹤0.01% of Knight Capital Group's portfolio in Q2 2013, its #2824 holding.
  • 12 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q2 2013.

Based on Knight Capital Group's 13F filing for Q2 2013, filed 8 Aug 2013.